SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ:CYTX) has extended the term and modified the focus of its current distribution agreement with GE Healthcare. GE Healthcare’s sales rights allow its sales force to sell Cytori technology in the research markets in select European markets and the US. In turn, Cytori has co-exclusive sales rights into the research markets while retaining primary rights to sell into all clinical markets. The term of this agreement has been extended through the end of 2011.
